Neumora Therapeutics Inc (NMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.49-13.96%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NMRA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
• Financial Guidance: The Company expects that its cash and cash equivalents as of June 30, 2026, will enable it to fund its operating plan into the third quarter of 2027.
Stated in 1 of 1 supplied quarters. Management reported: “FIRST QUARTER 2026 FINANCIAL RESULTS • Cash Position: As of March 31, 2026, Neumora had cash and cash equivalents of $147.1 million.” “SECOND QUARTER 2026 FINANCIAL RESULTS • Cash Position: As of June 30, 2026, Neumora had cash and cash equivalents of $116.8 million.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“• Financial Guidance: The Company expects that its cash and cash equivalents as of March 31, 2026, will enable it to fund its operating plan into the third quarter of 2027.”
The decrease was primarily due to a reduction in clinical trial costs, and lower personnel-related costs.
Stated in 1 of 1 supplied quarters. Management reported: “• R&D Expense: Research and development expenses for the first quarter of 2026 were $38.6 million, as compared to $52.2 million for the same period in 2025.” “• R&D Expense: Research and development expenses for the second quarter of 2026 were $29.3 million, as compared to $38.7 million for the same period in 2025.”
“The decrease was primarily due to a reduction in clinical trial costs, and lower personnel-related costs.”
NMRA-511 (Vasopressin 1a Receptor Antagonist): On Track to Report Data from Multiple Ascending Dose (MAD) Expansion Cohort in Alzheimer’s Disease (AD) Agitation in Fourth Quarter of 2026 Neumora plan…
Stated in 1 of 1 supplied quarters. Management reported: “Neumora plans to report data from a multiple ascending dose (MAD) expansion cohort evaluating higher doses of NMRA-511 in the second half of 2026 and to initiate a Phase 2 study with NMRA-511 in Alzheimer's disease agitation in the first quarter of 2027.” “NMRA-511 (Vasopressin 1a Receptor Antagonist): On Track to Report Data from Multiple Ascending Dose (MAD) Expansion Cohort in Alzheimer’s Disease (AD) Agitation in Fourth Quarter of 2026 Neumora plans to report data from a MAD expansion cohort evaluating higher doses of NMRA-511 in healthy elderly participants in the fourth quarter of 2026 and to initiate a Phase 2 study with NMRA-511 in Alzheimer's disease agitation by the end of 2026.”
“Neumora plans to report data from a multiple ascending dose (MAD) expansion cohort evaluating higher doses of NMRA-511 in the second half of 2026 and to initiate a Phase 2 study with NMRA-511 in Alzh…”
The Company expects to submit an IND in the fourth quarter of 2026 and to initiate a Phase 1 study by the end of 2026.
Stated in 1 of 1 supplied quarters. Management reported: “The Company expects to provide a program update in the second half of 2026 and for the program to enter the clinic in the first quarter of 2027.” “The Company expects to submit an IND in the fourth quarter of 2026 and to initiate a Phase 1 study by the end of 2026.”
“The Company expects to provide a program update in the second half of 2026 and for the program to enter the clinic in the first quarter of 2027.”
NMRA-898 (M4 Positive Allosteric Modulator): Phase 1 Data Expected in Second Half of 2026 Neumora is conducting a MAD study with NMRA-898 in healthy volunteers and patients with stable schizophrenia…
Stated in 1 of 1 supplied quarters. Management reported: “The Company expects to report data from the study in the second half of 2026.” “NMRA-898 (M4 Positive Allosteric Modulator): Phase 1 Data Expected in Second Half of 2026 Neumora is conducting a MAD study with NMRA-898 in healthy volunteers and patients with stable schizophrenia and expects to report data from the study in the second half of 2026.”
“The Company expects to report data from the study in the second half of 2026.”
Over the trailing year it converted 0.71x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.